研究人员正在寻找治疗慢性淋巴细胞白血病（CLL）或小淋巴细胞淋巴瘤（SLL）患者的新方法。CLL 和 SLL 是血癌的类型。研究人员想知道，与接受本研究标准治疗的患者相比，接受 nemtabrutinib 的患者是否能活得更久而不出现癌症生长、扩散或复发（无进展生存期）。
适应症：Chronic Lymphocytic Leukemia、Small Lymphocytic Lymphoma
入组条件
纳入标准
- Confirmed diagnosis of chronic lymphocytic leukemia (CLL)/ small lymphocytic lymphoma (SLL) and active disease clearly documented to have a need to initiate therapy
- Has previously untreated CLL/SLL participants without tumor protein 53 (TP53) aberrations and documented 11q status and immunoglobulin heavy chain gene (IGHV) mutational status
- The ability to swallow and retain oral medication
排除标准
- Has active hepatitis B virus (HBV) or hepatitis C virus (HCV) infection
- Has gastrointestinal dysfunction that may affect drug absorption (eg, gastric bypass surgery, gastrectomy)
- Has known additional malignancy that is progressing or has required active treatment within the past 3 years, except basal cell carcinoma of skin, squamous cell carcinoma of skin, or carcinoma in situ (eg, breast carcinoma, cervical cancer in situ) that have undergone potential curative therapy
- Has history of severe bleeding disorders
- Has not adequately recovered from major surgery or has ongoing surgical complications
入组条件维持 ClinicalTrials.gov 原始英文登记资料，实际入组资格以研究团队的正式评估与受试者知情同意书为准。资料来源：ClinicalTrials.gov，每两周自动更新，最后同步：2026年10月8日。